ARHGEF9 and central nervous system cancer: According to the results in Figures 6(a)–6(c), it could be seen that the proliferation of NHA cells was not significantly changed in SW1783 and U373 cells, while the proliferation activity of glioma cells decreased with the increased concentration of peptide ARHGEF9 from 10 μM to 100 μM. In CCK-8 assays, it was observed that peptide ARHGEF9 could block the proliferation of SW1783 and U373 cells (Figures 6(d) and 6(e)).